Comparison of efficacy and safety of second‐ and third‐generation TKIs for non‐small‐cell lung cancer with uncommon EGFR mutations

BACKGROUND: The efficacy of definite for non‐small‐cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor (EGFR) mutations has been preliminarily demonstrated. However, there is a paucity of data with which to compare the efficacy and safety of second‐ and third‐generation TKIs in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Hao, Yue, Xu, Manyi, Jin, Jianan, Si, Jinfei, Xu, Chunwei, Song, Zhengbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469645/
https://www.ncbi.nlm.nih.gov/pubmed/37306192
http://dx.doi.org/10.1002/cam4.6229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469645/
https://www.ncbi.nlm.nih.gov/pubmed/37306192
http://dx.doi.org/10.1002/cam4.6229

Ejemplares similares